Head to Head Comparison: Neuphoria Therapeutics (NASDAQ:NEUP) & Abeona Therapeutics (NASDAQ:ABEO)

Neuphoria Therapeutics (NASDAQ:NEUP) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Risk & Volatility

Neuphoria Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

Institutional & Insider Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by insiders. Comparatively, 5.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Neuphoria Therapeutics and Abeona Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-53.17%	-36.15%
Abeona Therapeutics	N/A	71.94%	44.09%

Analyst Ratings

This is a breakdown of current ratings for Neuphoria Therapeutics and Abeona Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	0	2	0	2.33
Abeona Therapeutics	1	0	4	0	2.60

Neuphoria Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 362.56%. Abeona Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 289.86%. Given Neuphoria Therapeutics’ higher possible upside, research analysts clearly believe Neuphoria Therapeutics is more favorable than Abeona Therapeutics.

Valuation & Earnings

This table compares Neuphoria Therapeutics and Abeona Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65 million	1.56	-$370,000.00	($4.88)	-0.93
Abeona Therapeutics	$3.50 million	79.43	-$63.73 million	$1.23	4.17

Neuphoria Therapeutics has higher revenue and earnings than Abeona Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Abeona Therapeutics beats Neuphoria Therapeutics on 10 of the 13 factors compared between the two stocks.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

About Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.